Brian Costell, MD
Epilepsy · Boca Raton, FLNPI 1174563688
Payments from drug & device makers
Across 2,774 payments — averaging $1429.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1.3M
- Eli Lilly$641K
- AbbVie$622K
- E.r. Squibb & Sons, L.L.C.$347K
- Argenx US, Inc.$258K
- Pfizer$155K
- plus $687K from 54 others
Across 21 payments — averaging $4978.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$43K
- GRT US Holding, Inc.$40K
- Eli Lilly$21K
What the payments were for
- Consulting fees$16,0893%
- Speaking & faculty fees$378,75781%
- Grants$440%
- Travel & lodging$28,3926%
- Food & beverage$45,27610%
- Education$3630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$71,758
- BOTOX$69,488
- AIMOVIG$61,242
- EMGALITY$56,200
- Leqembi$52,142
- REYVOW$32,950
- NURTEC ODT$22,441
- PRECIVITYAD2$19,421
- QULIPTA$18,219
- AJOVY$14,815
- VYEPTI$5,521
- VYVGART$2,150
- FIRDAPSE$1,500
- OXTELLAR XR$350
- Confirm Rx$318
- AUBAGIO$240
- AUSTEDO$218
- XEOMIN$149
- UPLIZNA$129
- ZEPOSIA$126
How this compares
$3,966,587 in reported general payments places this provider in the 95th percentile of 23 epilepsy providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 57 | $414,948 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 16 | $183,710 |
| IngrezzaValbenazine Tosylate | 12 | $105,254 |
| Nurtec OdtRimegepant Sulfate | 72 | $99,394 |
| CopaxoneGlatiramer Acetate | 15 | $84,681 |
| UbrelvyUbrogepant | 60 | $79,118 |
| Aimovig AutoinjectorErenumab-Aooe | 65 | $58,033 |
| NamzaricMemantine Hcl/Donepezil Hcl | 39 | $47,688 |
| BotoxOnabotulinumtoxina | 29 | $41,675 |
| RexultiBrexpiprazole | 27 | $39,542 |
| RytaryCarbidopa/Levodopa | 38 | $29,150 |
| ValtocoDiazepam | 12 | $20,524 |
| Emgality PenGalcanezumab-Gnlm | 26 | $19,632 |
| Oxtellar XrOxcarbazepine | 42 | $15,778 |
| Memantine Hcl | 450 | $15,282 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $234 | $414,94857 claims |
| AbbVieUbrelvy, Namzaric, Botox, Qulipta | $621,985 | $182,275139 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $495 | $105,25412 claims |
| PfizerNurtec Odt | $154,657 | $99,39472 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $16,690 | $84,68115 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $149 | $39,54227 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $878 | $33,62677 claims |
| UCB, Inc.Briviact, Vimpat | $10,716 | $30,04124 claims |
| Neurelis, Inc.Valtoco | $553 | $20,52412 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $474 | $15,77842 claims |
| Scilex Pharmaceuticals Inc.Elyxyb | $336 | $10,05411 claims |
| MerckBelsomra | $107 | $5,43812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 23 epilepsy providers in Florida.
Other epilepsy in Boca Raton
- Andrew LermanMiami$4.5M
- William TatumJacksonville$574K
- Alberto Pinzon ArdilaMiami$351K
- Yue WangGainesville$45K
- Miguel Melo-BicchiMiami$44K
- Jaivir RathoreOrlando$38K
- Dipali NemadeOrlando$38K
- Mohamed NasserWeston$28K
- Jean CibulaGainesville$24K
- Brin FreundJacksonville$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.